Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 24Kidney Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 5von Hippel-Lindau Disease 2Neoplasm Metastasis 2Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neuroectodermal Tumors, Primitive 1Metastatic Castration-Resistant Prostate Cancer 1Hemangioblastoma 1Glioblastoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1

Interventions

Nivolumab 14Ipilimumab 11Specimen Handling 10CTLA-4 Antigen 7pembrolizumab 6cabozantinib 6Sunitinib 6Magnetic Resonance Spectroscopy 6Axitinib 5pazopanib 4Biopsy 4Radiosurgery 3lenvatinib 2fludarabine 2Everolimus 2Blood Specimen Collection 2tivozanib 1sodium-iodide symporter 1sitravatinib 1belzutifan 1atezolizumab 1aldesleukin 1Zoledronic Acid 1Tissue Banks 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Pluvicto 1Nephrectomy 1Molecular Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × belzutifan × Genitourinary × Clear all
NCT07179770 2025-09-23

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

NYU Langone Health

Phase 1 Recruiting
12 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡